Decipher Lethal Prostate Cancer Biology - Urine Metabolomics

20 Jan 20264 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · SCREENING study · Significant Prostate Cancer · Enrollment 2000 · Sponsor: National Taiwan University Hospital

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Oncology on 20 Jan 2026. The item focuses on Decipher Lethal Prostate Cancer Biology - Urine Metabolomics. Open the detail page to review the full original feed content.

Source Reference

Read the full original publication from the source journal or publisher link below.

DOI

NCT03237702

Open Original Source More Feed Items

Related by Condition/Drug

Autonomous pathology research using agentic AI shows potential in oncology

Oncology • 05 May 2026

CCNE1 Gain Defines a Therapy-Refractory Gastric Cancer Subtype

Oncology • 28 Apr 2026

ClinicalTrialsRelated by Conditionprostate cancer

Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy

Oncology • 08 Apr 2026

ClinicalTrialsRelated by Conditionprostate cancer

A Phase Ib/II Open-Label Study Of AMO959 With 177Lu-PSMA-617 In Combination With An ARPI In PSMA

Oncology • 01 Apr 2026

Genome-wide methylome profiling of cell-free DNA enables prognostication of patients with castration-resistant prostate cancer

Oncology • 10 Apr 2026

Prostate MRI Beyond Diagnosis: Prognostic Value After Radical Prostatectomy

Oncology • 02 Apr 2026

Feed Metadata

Source

ClinicalTrials.gov